MISSION VIEJO, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) today announced preliminary results showing that AEOL 10150 promotes survival in a proof of principle study conducted in a non-human primate model of Pulmonary Acute Radiation Syndrome (ARS). The study included 13 animals, of which 6 were control animals and 7 received AEOL 10150. While none of the six control animals survived the 180 day study period, 2 of the 7 (or 28.5%) of the animals receiving drug survived.
